Sandoz calls for half-price biosims

Sandoz has released a white paper outlining some bold moves the Federal Government can take to encourage the use of biosimilars.

The white paper, Pioneering Access for Patients Through Biosimilar Medicines, notes that the uptake for key anti-TNF biosimilar medicines in Australia was 35 per cent in 2023, compared to an OECD average of 67 per cent. That includes biosimilars of AbbVie's Humira, J&J's Remicade, and Pfizer's Enbrel, despite these being the highest earning biosimilars on the PBS.

"The Sandoz white paper marks a pivotal moment in our ongoing and collaborative efforts to pioneer healthcare access and affordability for patients across the country," Sandoz Head of Medical Affairs and Policy, Chad Rieger, said.